Curanex Pharmaceuticals Inc Common Stock (CURX) — Working Capital to Net Assets Ratio
Curanex Pharmaceuticals Inc Common Stock (CURX) has a Working Capital to Net Assets ratio of 99.6% as of September 2025. Working capital of $14.23 Million (current assets of $14.42 Million minus current liabilities of $185.96K) is measured against net assets of $14.29 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. See how leveraged is Curanex Pharmaceuticals Inc Common Stock's balance sheet to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Curanex Pharmaceuticals Inc Common Stock Working Capital to Net Assets (2022–2024)
This chart shows how Curanex Pharmaceuticals Inc Common Stock's Working Capital to Net Assets ratio has evolved across 3 annual periods from 2022 to 2024. As of September 2025, the ratio stands at 99.6%, reflecting working capital of $14.23 Million against net assets of $14.29 Million USD. Check Curanex Pharmaceuticals Inc Common Stock tangible book value ratio to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for Curanex Pharmaceuticals Inc Common Stock (2022–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Curanex Pharmaceuticals Inc Common Stock from 2022 to 2024, covering 3 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see market value of Curanex Pharmaceuticals Inc Common Stock.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 100.0% | $503.36K | $503.36K | $517.93K | $14.57K | ▲ +0.0 pp |
| 2023 | 100.0% | $60.09K | $60.09K | $74.37K | $14.28K | ▲ +0.0 pp |
| 2022 | 100.0% | $10.23K | $10.23K | $10.23K | $0.00 | — |